Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1051-1070 , December 2007

Diagnostic uncertainty in the inflammatory myopathies

  • M. Anthony Verity, MD (Emeritus Professor of Pathology and Neuropathology)

      Affiliations

    • Corresponding Author InformationTel.: +1 310 825 7230; Fax: +1 310 206 8290.

References 

  1. Mastaglia FL, Garlepp MJ, Phillips BA, et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 2003 Apr;27(4):407–425
  2. Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with Simvastatin. Lancet. 1997 May 31;349(9065):1600–1601
  3. Hohlfeld R, Engel AG, Ii K, et al. Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. The New England Journal of Medicine. 1991 Mar 28;324(13):877–881
  4. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular Disorders. 2007 Feb;17(2):194–200Epub 2007 Jan 22
  5. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975 Dec;98(4):637–666
  6. Nagaraju K, Casciola_Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis and Rheumatism. 2005 Jun;52(6):1824–1835
  7. Piccolo F, Moore SA, Ford GC, et al. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb–girdle muscular dystrophies. Annals of Neurology. 2000 Dec;48(6):902–912
  8. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathology and Applied Neurobiology. 2002 Dec;28(6):461–470
  9. Gallardo E, Rojas-Garcia R, de Luna N, et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology. 2001 Dec 11;57(11):2136–2138
  10. Rowin J, Meriggioli MN, Cochran EJ, et al. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscular Disorders. 1999 Oct;9(6-7):417–420
  11. Argov Z, Sadeh M, Mazor K, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain. 2000 Jun;123(Pt 6):1229–1237
  12. Han R, Bansal D, Miyake K, et al. Dyofeslin-mediated repair protects the heart from stress-induced left ventricular injury. Journal of Clinical Investigation. 2007 Jul;117(7):1805–1813
  13. van der Pas J, Hengstman GJ, ter Laak HJ, et al. Diagnostic value of MHC class 1 staining in idiopathic inflammatory myopathies. Journal of Neurology, Neurosurgery and Psychiatry. 2004 Jan;75(1):136–139
  14. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991 Jun;41(6):936–939
  15. Authier FJ, Kondo H, Ghnassia RT, et al. Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology. 1996 May;46(5):1448–1451
  16. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). Lancet. 1998 Aug 1;352(9125):347–352
  17. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain. 2001 Sep;124(Pt 9):1821–1831
  18. Bassez G, Authier FJ, Lechapt-Zalcman E, et al. Inflammatory myopathy with abundant macrophages (IMAM): a condition sharing similarities with cytophagic histiocytic panniculitis and distinct from macrophagic myofasciitis. Journal of Neuropathology and Experimental Neurology. 2003 May;62(5):464–474
  19. Yasuda S, Tsutsumi A, Nakabayashi T, et al. Haemophagocytic syndrome in a patient with dermatomyositis. British Journal of Rheumatology. 1998 Dec;37(12):1357–1358No abstract available
  20. Papo T, Andre MH, Amoura Z, et al. The spectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus. Journal of Rheumatology. 1999 Apr;26(4):927–930
  21. Madaule S, Porte L, Couret B, et al. Fatal haemophagocytic syndrome in the course of dermatomyositis with anti-Mi2 antibodies. Rheumatology (Oxford). 2000 Oct;39(10):1157–1158
  22. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology (Oxford). 1999 May;38(5):397–400
  23. Oldfors A, Moslemi AR, Fyhr IM, et al. Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. Journal of Neuropathology and Experimental Neurology. 1995 Jul;54(4):581–587
  24. Moslemi AR, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Human Mutation. 1997;10(5):381–386
  25. Carpenter S, Karpati G, Heller I, et al. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology. 1978 Jan;28(1):8–17
  26. Eisen A, Berry K, Gibson G. Inclusion body myositis (IBM): myopathy or neuropathy?. Neurology. 1983 Sep;33(9):1109–1114
  27. Layzer RB, Shearn MA, Satya-Murti S. Eosinophilic polymyositis. Annals of Neurology. 1977 Jan;1(1):65–71
  28. Stark RJ. Eosinophilic polymyositis. Archives of Neurology. 1979 Nov;36(11):721–722
  29. Hall FC, Krausz T, Walport MJ. Idiopathic eosinophilic myositis. Quarterly Journal of Medicine. 1995 Aug;88(8):581–586
  30. Serratrice G, Pellissier JF, Cros D, et al. Relapsing eosinophilic perimyositis. Journal of Rheumatology. 1980 Mar–Apr;7(2):199–205
  31. Fang MA, Verity MA, Paulus HE. Subacute perimyositis. Journal of Rheumatology. 1988 Aug;15(8):1291–1293
  32. Bjelle A, Henriksson KG, Hofer PA. Polymyositis in eosinophilic fasciitis. Review and case report. European Neurology. 1980;19(2):128–137No abstract available
  33. Winchester RJ, Koffler D, Litwin SD, et al. Observations on the eosinophilia of certain patients with rheumatoid arthritis. Arthritis and Rheumatism. 1971 Sep–Oct;14(5):650–665
  34. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Annals of Internal Medicine. 1982 Jul;97(1):78–92Review
  35. Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Seminars in Arthritis and Rheumatism. 1988 May;17(4):221–231
  36. Kamm MA, Dennett X, Byrne E. Relapsing eosinophilic myositis–a cause of pseudothrombophlebitis in an alcoholic. Journal of Rheumatology. 1987 Aug;14(4):831–834
  37. Hall C, Mongey AB. Unusual presentation of polyarteritis nodosa. Journal of Rheumatology. 2001 Apr;28(4):871–873
  38. Nakamura T, Tomoda K, Yamamura Y, et al. Polyarteritis nodosa limited to calf muscles: a case report and review of the literature. Clinical Rheumatology. 2003 May;22(2):149–153Review
  39. Buchanan R, Sworn MJ, Mousley JM. Angiolymphoid hyperplasia with eosinophilia involving skeletal muscle. Histopathology. 1980 Mar;4(2):197–204
  40. Verity MA. Angiolymphoid hyperplasia with eosinophilia: myopathic Kimura's disease. Journal of Neuropathology and Experimental Neurology. 1992;51:356

PII: S1521-6942(07)00112-X

doi: 10.1016/j.berh.2007.10.004

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1051-1070 , December 2007

Article Tools

* Image Usage & Resolution